Gilead Sciences

Page 2 of 2

Gilead coronavirus trial
Newsletters

Can Gilead tame the coronavirus?

By
February 27, 2020
Gilead remdesivir clinical trials
Health

Gilead’s coronavirus treatment is barreling its way into new clinical trials

By
February 27, 2020
Truvada

Drug-Company Patents vs. the Public Good: Should the NIH Break This Medication Patent?

By
March 5, 2019
Gilead Takes AIDS Drug-Cocktail Approach To Fighting Cancer
Health

The FDA Just Approved a Second Revolutionary Gene Therapy. A Third Is Probably on the Way

By
October 19, 2017
3 Surprising Facts from America’s Fastest Growing Companies
Leadership

3 Surprising Facts from America’s Fastest Growing Companies

By
September 12, 2016
Why the Fight Against AIDS Still Matters, in One Chart

Why the Fight Against AIDS Still Matters, in One Chart

By
August 23, 2016
SAFRICA-HEALTH-AIDS-CONFERENCE
Health

The Incredible New Advances in the Fight Against HIV/AIDS

By
July 21, 2016
Stocks Close Sharply Lower As Oil Prices Continue Decline
Finance

These Biopharma Companies Are the World’s Top Shareholder Value Creators

By
May 3, 2016
Inside of a Gilead Sciences Lab
Health

Gilead Ordered to Pay Merck $200 Million in Hepatitis C Dispute

By
March 25, 2016
Key Speakers At The Stanford Institute For Economic Policy Research Forum
Leadership

Gilead CEO John Martin Is Stepping Down After 20 Years

By
January 29, 2016
These Fortune 500 companies leapfrogged the rest
Finance

These Fortune 500 companies leapfrogged the rest

By
June 19, 2015
Key Speakers At The Stanford Institute For Economic Policy Research Forum
Finance

Gilead CEO: “We are taking suggestions” on companies to buy

By
May 1, 2015
Biotech “bubble” popped, time to buy again?
Finance

Biotech “bubble” popped, time to buy again?

By
March 27, 2015
Key Speakers At The Stanford Institute For Economic Policy Research Forum
Leadership

Step aside Wall Street, small pharma CEO pay reaches for the sky

By
January 5, 2015

Most Popular